Detalles de la búsqueda
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37879077
2.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
; 2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38551807
3.
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Am J Hematol
; 98(3): 493-501, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600670
4.
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Am J Hematol
; 98(8): 1196-1203, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183966
5.
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
Am J Hematol
; 97(9): 1135-1141, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35713551
6.
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Cancer
; 127(18): 3381-3389, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34138471
7.
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Cancer
; 127(15): 2648-2656, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33793964
8.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cancer
; 127(12): 2025-2038, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740268
9.
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Acta Haematol
; 144(3): 285-292, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33238261
10.
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.
Am J Hematol
; 95(7): 734-739, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32170867
11.
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
Am J Hematol
; 95(2): 144-150, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31682008
12.
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Cancer
; 125(15): 2579-2586, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30985931
13.
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Am J Hematol
; 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38607091
14.
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Am J Hematol
; 94(12): 1388-1395, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31595534
15.
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
Lancet Oncol
; 19(2): 240-248, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29352703
16.
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Cancer
; 124(20): 4044-4055, 2018 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30307611
17.
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Blood
; 128(4): 504-7, 2016 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27235138
18.
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Am J Hematol
; 93(1): 91-99, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047158
19.
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Cancer
; 123(2): 294-302, 2017 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27602508
20.
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Cancer
; 123(19): 3717-3724, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28608976